511 related articles for article (PubMed ID: 16788093)
1. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
Efird LE; Kockler DR
Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
[TBL] [Abstract][Full Text] [Related]
2. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.
Blackmer AB; Oertel MD; Valgus JM
Ann Pharmacother; 2009 Oct; 43(10):1636-46. PubMed ID: 19737996
[TBL] [Abstract][Full Text] [Related]
3. Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?
Badger NO
J Pharm Pract; 2010 Jun; 23(3):235-8. PubMed ID: 21507819
[TBL] [Abstract][Full Text] [Related]
4. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
[TBL] [Abstract][Full Text] [Related]
5. Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.
Creekmore FM; Oderda GM; Pendleton RC; Brixner DI
Pharmacotherapy; 2006 Oct; 26(10):1438-45. PubMed ID: 16999654
[TBL] [Abstract][Full Text] [Related]
6. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
Papadopoulos S; Flynn JD; Lewis DA
Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773
[TBL] [Abstract][Full Text] [Related]
9. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
10. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
Lobo B; Finch C; Howard A; Minhas S
Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
[TBL] [Abstract][Full Text] [Related]
11. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
[TBL] [Abstract][Full Text] [Related]
12. Fondaparinux cross-reacts with heparin antibodies in vitro in a patient with fondaparinux-related thrombocytopenia.
Pistulli R; Oberle V; Figulla HR; Yilmaz A; Pfeifer R
Blood Coagul Fibrinolysis; 2011 Jan; 22(1):76-8. PubMed ID: 21076279
[TBL] [Abstract][Full Text] [Related]
13. [Management of heparin-induced thrombocytopenia].
Aouizerate P; Guizard M
Therapie; 2002; 57(6):577-88. PubMed ID: 12666266
[TBL] [Abstract][Full Text] [Related]
14. Treatment of heparin-induced thrombocytopenia with fondaparinux.
Harenberg J; Jörg I; Fenyvesi T
Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
[TBL] [Abstract][Full Text] [Related]
15. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies.
Greinacher A; Gopinadhan M; Günther JU; Omer-Adam MA; Strobel U; Warkentin TE; Papastavrou G; Weitschies W; Helm CA
Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2386-93. PubMed ID: 16873726
[TBL] [Abstract][Full Text] [Related]
16. [Heparin-induced thrombocytopenia after elective hip joint replacement with postoperative prevention of thromboembolism with low-molecular-weight heparin].
Marx A; Huhle G; Hoffmann U; Wang LC; Schüle B; Jani L; Harenberg J
Z Orthop Ihre Grenzgeb; 1999; 137(6):536-9. PubMed ID: 10666863
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery.
Bucci C; Geerts WH; Sinclair A; Fremes SE
Am J Cardiol; 2011 Feb; 107(4):591-4. PubMed ID: 21184996
[TBL] [Abstract][Full Text] [Related]
18. Fondaparinux: does it cause HIT? Can it treat HIT?
Warkentin TE
Expert Rev Hematol; 2010 Oct; 3(5):567-81. PubMed ID: 21083474
[TBL] [Abstract][Full Text] [Related]
19. Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.
Modi C; Satani D; Cervellione KL; Cervantes J; Gintautas J
Proc West Pharmacol Soc; 2009; 52():5-7. PubMed ID: 22128408
[TBL] [Abstract][Full Text] [Related]
20. From heparins to factor Xa inhibitors and beyond.
Alban S
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():12-20. PubMed ID: 15701143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
